Portal de investigación
Direct-acting Antivirals for the Treatment of Kidney Transplant Patients With Chronic Hepatitis C Virus Infection in Spain: A Long-term Prospective Observational Study.
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- González-Corvillo C
- Sánchez-Fructuoso A
- Perelló M
- Alonso A
- Mazuecos A
- Jiménez C
- Zárraga S
- Paul J
- Lauzurica R
- Hernández D
- Guirado L
- Franco A
- Ruiz JC
- Llorente S
- Crespo M
- Rodríguez-Benot A
- de Gracia Guindo MDC
- Díaz-Corte C
- Gentil MÁ
Abstract
Direct-acting antivirals (DAA) allow effective and safe eradication of hepatitis C virus (HCV) in most patients. There are limited data on the long-term effects of all-oral, interferon-free DAA combination therapies in kidney transplant (KT) patients infected with HCV. Here we evaluated the long-term tolerability, efficacy, and safety of DAA combination therapies in KT patients with chronic HCV infection.
Datos de la publicación
- ISSN/ISSNe:
- 2373-8731, 2373-8731
- Tipo:
- Article
- Páginas:
- -
- PubMed:
- 32095505
- Factor de Impacto:
- 0,513 SCImago ℠
- Cuartil:
- Q3 SCImago ℠
Transplantation Direct LIPPINCOTT WILLIAMS & WILKINS
Citas Recibidas en Web of Science: 2
Documentos
- No hay documentos
Filiaciones
Cita
González C,BENEYTO I,Sánchez A,Perelló M,Alonso A,Mazuecos A,Jiménez C,Zárraga S,Paul J,Lauzurica R,Hernández D,Guirado L,Franco A,Ruiz JC,Llorente S,Crespo M,Rodríguez A,de Gracia MDC,Díaz C,Gentil MÁ. Direct-acting Antivirals for the Treatment of Kidney Transplant Patients With Chronic Hepatitis C Virus Infection in Spain: A Long-term Prospective Observational Study. Transplant. Direct. 2019. 5. (12):e510.